Treatments for metastatic breast cancer

Last medical review:

Metastatic breast cancer is cancer that has spread to other parts of the body. Cancer that has spread at the time of diagnosis is stage 4 breast cancer. Metastatic breast cancer can also mean cancer that has come back (recurred) after it has been treated.

Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.

The treatments offered for metastatic breast cancer depend on:

  • the hormone receptor status of the cancer
  • the HER2 status of the cancer
  • any other genetic changes to the cancer cells
  • the type and number of treatments you have had for breast cancer, including treatments for metastatic disease
  • where the cancer has spread
  • if the cancer is causing any symptoms
  • your overall health
  • any medical problems you have
  • your lifestyle and what you prefer or want

Hormone therapy

Hormone therapy is offered for hormone receptor–positive breast cancer that has spread to the bones and soft tissues, such as muscles or fat. It is also given when the cancer has spread to internal organs, such as the liver, lungs or brain, but it isn't causing any symptoms.

Metastatic breast cancer is treated with an aromatase inhibitor such as:

  • letrozole (Femara)
  • anastrozole (Arimidex)
  • exemestane (Aromasin)

If you are premenopausal you will be given a gonadotropin-releasing hormone (GnRH) agonist along with an aromatase inhibitor.

If you have been taking an aromatase inhibitor and the cancer has spread, your healthcare team will switch you to a different aromatase inhibitor.

Tamoxifen may be offered if you can't take aromatase inhibitors or if you have severe side effects from them.

Find out more about hormone therapy for breast cancer.

Chemotherapy

Chemotherapy is given for metastatic, hormone receptor–negative breast cancer. It is also offered for hormone receptor–positive breast cancer that has spread to internal organs and is causing symptoms.

There is no standard drug or drug combination for metastatic breast cancer. Chemotherapy is given as long as the cancer responds to it and the side effects do not cause problems. Once the cancer no longer responds to the treatment, a different drug or treatment may be offered.

Chemotherapy drugs are often used alone to treat metastatic breast cancer. This is because a single drug causes fewer side effects than a combination of drugs. Chemotherapy is given as long as the side effects do not cause problems and the cancer does not grow.

The following drugs may be used (usually as a single drug but sometimes combined with one another):

  • anthracycline drugs such as doxorubicin, epirubicin, or pegylated liposomal doxorubicin
  • taxane drugs such as paclitaxel, docetaxel, or nab-paclitaxel
  • platinum drugs such as carboplatin or cisplatin
  • gemcitabine
  • vinorelbine
  • cyclophosphamide
  • capecitabine
  • fluorouracil (also called 5-fluorouracil or 5-FU)
Sometimes a targeted therapy drug will be added to chemotherapy to treat metastatic breast cancer.

Find out more about chemotherapy for breast cancer.

Targeted therapy

Targeted therapy for metastatic breast cancer is often given in combination with chemotherapy or hormone therapy. The targeted therapy treatment offered to you by your healthcare team will be based on any targeted therapy drugs you have already had, any other treatments you have had, the number of treatments you have had, and the hormone receptor status and HER2 status of the cancer.

Metastatic breast cancer that is hormone-receptor positive and HER2 positive may be treated with the following targeted therapy drugs:

  • trastuzumab (Herceptin and biosimilars)
  • pertuzumab (Perjeta)
  • trastuzumab and pertuzumab combination (Phesgo)
  • trastuzumab emtansine (Kadcyla or T-DM1)
  • trastuzumab deruxtecan (Enhertu)
  • lapatinib (Tykerb)
  • neratinib (Nerlynx)
  • tucatinib (Tukysa)

Metastatic breast cancer that is hormone-receptor positive and HER2 negative may be treated with the following targeted therapy drugs:

  • everolimus (Afinitor)
  • alpelisib (Piqray)
  • ribociclib (Kisqali)
  • abemaciclib (Verzenio)
  • palbociclib (Ibrance)
  • capivasertib (Truqap)

Metastatic breast cancer that is HER2 negative and has BRCA gene mutations may be treated with the following targeted therapy drugs:

  • olaparib (Lynparza)
  • talazoparib (Talzenna)

Find out more about targeted therapy for breast cancer.

Radiation therapy

External radiation therapy may be used to relieve pain, control the symptoms or prevent future symptoms of metastatic breast cancer. It is used to treat breast cancer that has spread to:

  • lymph nodes around the breast, under the arms or around the collarbone
  • the bones (bone metastases)
  • the brain (brain metastases)
  • the lungs (lung metastases) – to treat coughing or breathing problems

It may also be used to treat cancer that has come back in the breast. You may not be able to have radiation therapy if it has already been used to treat some areas.

Find out more about radiation therapy for breast cancer.

Surgery

Surgery is rarely done to remove the tumour in the breast when the cancer has spread to other parts of the body.

Surgery may be used to:

  • remove a single metastasis from a lung or the liver
  • remove a metastasis from the brain (in rare cases)
  • treat a broken bone or spinal cord compression if the cancer has spread to the bones

Find out more about surgery for breast cancer.

Clinical trials

Many clinical trials in Canada are open to people with breast cancer. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.

If you can’t have or don't want cancer treatment

You may want to consider a type of care to make you feel better without treating the cancer itself. This may be because the cancer treatments don't work anymore, they aren't likely to improve your condition or they may cause side effects that are hard to cope with. There may also be other reasons why you can’t have or don't want cancer treatment.

Talk to your healthcare team. They can help you choose care and treatment for advanced cancer.

Expert review and references

  • Jaime Escallon, MD, FACS, FRCSC
  • Robert Olson , MD, FRCPC, MSc
  • American Cancer Society. Treatment of Stage IV (Metastatic) Breast Cancer. August, 2022: https://www.cancer.org/.
  • Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. Journal of Clinical Oncology. 2021: 39: 3959-3977.
  • Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology. 2021: 32(12): 1475-1495.
  • Hong K, Yao L, Sheng X, Ye D, Guo Y. Neoadjuvant therapy of cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy in HR+/HER2- breast cancer: a systematic review and meta-analysis. Oncology Research and Treatment. 2021: 44:557-567.
  • Jagsir R, King TA, Lehman C, Morrow M, Harris JR, Burstein HJ. Malignant tumors of the breast. DeVita VT Jr., Lawrence TS, Rosenberg SA, eds.. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019: 79:1269–1317.
  • Kyriazoglou A, Kaparelour M, Goumas G, Liontos M, Zakopoulou R, Zografos E, et al . Immunotherapy in HER2-positive breast cancer: a systematic review. Breast Care. 2022: 17:63-70.
  • Department of Clinical Effectiveness. Breast Cancer - Metastatic Disease. MD Anderson Cancer Center; 2022.
  • Moy, B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, et al. Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update. Journal of Clinical Oncology. 2021: 39: 3938-3958.
  • Moy, B, Rumble RB, Carey LB. Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline rapid recommendation update. Journal of Clinical Oncology. 2022: 39: 3938-3958.
  • PDQ® Adult Treatment Editorial Board. Breast Cancer Treatment (PDQ®) – Health Professional Version. Bethesda, MD: National Cancer Institute; 2022: https://www.cancer.gov/.
  • National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 4.2022).

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society